Literature DB >> 10411115

Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women.

A Gürlek1, O Gedik.   

Abstract

In this cross-sectional study, we evaluated 15 premenopausal women to elucidate whether bone turnover is increased and bone mineral density is reduced due to endogenous subclinical hyperthyroidism. Each patient had normal free thyroxine (FT4) and free triiodothyronine (FT3) levels associated with a stable suppression (<0.1 mU/L) of serum thyrotropin (TSH) levels during a period ranging between 6 and 11 months. Metabolic parameters of bone turnover (serum osteocalcin, bone specific alkaline phosphatase, procollagen I C-terminal peptide reflecting bone formation; urinary deoxypyridinoline and calcium excretion reflecting bone resorption) were assessed. Bone mineral density was measured at lumbar 1-4 vertebrae, femoral neck, and the forearm (midshaft radius and distal radius) by dual energy x-ray absorptiometry. All measurements were compared with 15 healthy age-, height-, and weight-matched premenopausal women who served as control group. Our findings suggest that endogenous subclinical hyperthyroidism is not associated with increased bone turnover, and bone mineral density is not reduced in premenopausal women, at least in the short term.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411115     DOI: 10.1089/thy.1999.9.539

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  10 in total

1.  Endogenous subclinical hyperthyroidism may not lead to bone loss in premenopausal women.

Authors:  T Saler; S Ahbab; Z A Sağlam; Ş Ö Keşkek; S Kurnaz
Journal:  Hippokratia       Date:  2014 Jul-Sep       Impact factor: 0.471

2.  Thyroid-stimulating hormone, thyroid hormones, and bone loss.

Authors:  Mone Zaidi; Terry F Davies; Alberta Zallone; Harry C Blair; Jameel Iqbal; Surinder S Moonga; Jeffrey Mechanick; Li Sun
Journal:  Curr Osteoporos Rep       Date:  2009-07       Impact factor: 5.096

3.  Favorable clinical heart and bone effects of anti-thyroid drug therapy in endogenous subclinical hyperthyroidism.

Authors:  S Buscemi; S Verga; S Cottone; G Andronico; L D'Orio; V Mannino; D Panzavecchia; F Vitale; G Cerasola
Journal:  J Endocrinol Invest       Date:  2007-03       Impact factor: 4.256

4.  The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism.

Authors:  Bernadette Biondi; Luigi Bartalena; David S Cooper; Laszlo Hegedüs; Peter Laurberg; George J Kahaly
Journal:  Eur Thyroid J       Date:  2015-08-26

Review 5.  Subclinical thyroid disorders: the menace of the Trojan horse.

Authors:  L H Duntas
Journal:  J Endocrinol Invest       Date:  2003-05       Impact factor: 4.256

Review 6.  Expanding the Role of Thyroid-Stimulating Hormone in Skeletal Physiology.

Authors:  Ramkumarie Baliram; Rauf Latif; Mone Zaidi; Terry F Davies
Journal:  Front Endocrinol (Lausanne)       Date:  2017-10-03       Impact factor: 5.555

7.  Risk of Osteoporotic Fractures after Thyroid-stimulating Hormone Suppression Therapy in Patients with Thyroid Cancer.

Authors:  Youjin Lee; Byung-Ho Yoon; Seeyoun Lee; Youn Kyung Chung; Young-Kyun Lee
Journal:  J Bone Metab       Date:  2019-02-28

8.  Influence of Thyroid-stimulating Hormone Suppression Therapy on Bone Mineral Density in Patients with Differentiated Thyroid Cancer: A Meta-analysis.

Authors:  Byung-Ho Yoon; Youjin Lee; Hyun Jin Oh; Sung Han Kim; Young-Kyun Lee
Journal:  J Bone Metab       Date:  2019-02-28

9.  Metabolic and clinical consequences of hyperthyroidism on bone density.

Authors:  Jagoda Gorka; Regina M Taylor-Gjevre; Terra Arnason
Journal:  Int J Endocrinol       Date:  2013-07-22       Impact factor: 3.257

Review 10.  Thyroid Hormone Diseases and Osteoporosis.

Authors:  Alessandro P Delitala; Angelo Scuteri; Carlo Doria
Journal:  J Clin Med       Date:  2020-04-06       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.